BioMarin Pharmaceutical Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Alexander Hardy
- Full Time Employees
- 3,221
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 770 Lindaro Street San Rafael CA United States 94901
- IPO Date
- Jul 23, 1999
- CIK
- 0001048477
- Website
- biomarin.com
- Similar Companies
- Business
- BioMarin Pharmaceutical Inc. is a global biotechnology company specializing in the development and commercialization of innovative therapies for rare genetic diseases and serious medical conditions. Founded in 1997 and headquartered in San Rafael, California, BioMarin offers a portfolio of approved products including VOXZOGO for achondroplasia and hypochondroplasia; ROCTAVIAN for severe hemophilia A; BRINEURA for Batten disease; and ALDURAZYME for mucopolysaccharidosis I. The company’s product pipeline includes advanced investigational therapies such as BMN 351 for Duchenne muscular dystrophy, BMN 349 for alpha-1 antitrypsin deficiency-associated liver disease, and BMN 333 for multiple growth disorders. BioMarin employs multiple treatment modalities including enzyme replacement therapies, oligonucleotide therapeutics, and gene therapies. Recent major developments include BioMarin’s acquisition of Inozyme Pharma in mid-2025 for approximately $270 million, which expanded BioMarin’s portfolio with INZ-701, a late-stage enzyme replacement therapy in Phase 3 development targeting ENPP1 deficiency, a rare genetic disorder affecting blood vessels and connective tissues. Additionally, BioMarin advanced its pivotal Phase 3 clinical trial for VOXZOGO in hypochondroplasia with topline data expected in 2026 and a potential product launch in 2027. The company also strengthened its research capabilities through collaborations such as the partnership with Deep Genomics to apply artificial intelligence for oligonucleotide drug discovery. In 2023 and 2024, BioMarin focused its R&D strategy by prioritizing three key clinical assets and discontinuing four earlier-stage candidates, accelerating the pace of new drug filings and advancing pipeline productivity. BioMarin operates primarily in the rare disease biopharmaceutical sector with a focus on genetic and lysosomal storage disorders, serving patients across North America, Europe, and other global markets. The company integrates research, development, manufacturing, and commercialization functions, leveraging scientific expertise to bring first- or best-in-class genetic therapies to market. BioMarin’s efforts are supported by strategic alliances and a growing portfolio of proprietary products and clinical-stage candidates aimed at addressing high unmet medical needs in genetic diseases.
Company News
Traders Buy Large Volume of BioMarin Pharmaceutical Call Options (NASDAQ:BMRN)
BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
BioMarin to Participate in Upcoming Investor Conferences
BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript
BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
BioMarin Reports Third Quarter 2026 Financial and Operating Results
BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
Quadrant Capital Group LLC Makes New $564,000 Investment in BioMarin Pharmaceutical Inc. $BMRN
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
BioMarin Pharmaceutical Inc. $BMRN Stock: Assenagon Asset Management S.A. Lowers Position
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
Financial Review: Relay Therapeutics (NASDAQ:RLAY) & BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
BioMarin Appoints Cara Bauer as Chief People Officer
BioMarin reports five-year Pompe disease data showing durable motor function